Happy Holidays! I hope you are enjoying this exciting season with family, friends, colleagues, and lots of holiday cheer. As you celebrate and reflect on a prosperous 2016, we have posted new stem cell industry coverage to help you prepare for 2017. This week in stem cells we cover cell therapy in Asia, exosomes going exponential, a massive $225M series A financing, and much more. [Read more…]
To understand the benefits of cord blood vs. bone marrow vs. peripheral blood, it is important to understand the use of each for hematopoietic stem cell transplantation (HSCT).
Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood. It is performed for patients with cancers of the blood or bone marrow, such as leukemia and multiple myeloma, making it the leading type of cell therapy performed worldwide. [Read more…]
If you are an investor considering an opportunity related to induced pluripotent stem cells (iPSCs), the market can initially appear technical and confusing. However, if you focus on a few key points of understanding, you’ll be able to assess the technical attributes that matter, including what defines the cell type, advantages and disadvantages, key events driving market growth, and opportunities for commercialization.
To begin, the best place to start is with a clear definition of the cell type.
Definition of Induced Pluripotent Stem Cells
Induced pluripotent stem cells (iPSCs) are a type of pluripotent stem cell artificially derived from a non-pluripotent cell – typically an adult somatic cell, by inducing a ‘forced’ expression of specific gene. [Read more…]